Assessment of mutations in Ki-ras and p53 in colon cancers from azoxymethane- and dimethylhydrazine-treated rats

Molecular Carcinogenesis

Volumn 19, Issue 2, 1997, Pages 137-144

  Erdman, Steven H ^a,b   Wu, H David ^a   Hixson, Lee J ^a   Ahnen, Dennis J ^c   Gerner, Eugene W ^a,d  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

Author keywords

Carcinogenesis; Colon cancer; Oncogene; p53; Tumor suppressor gene

Indexed keywords

AZOXYMETHANE; DIMETHYLHYDRAZINE; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLON CARCINOGENESIS; CONTROLLED STUDY; GENE MUTATION; MALE; NONHUMAN; ONCOGENE K RAS; PRIORITY JOURNAL; RAT; TUMOR SUPPRESSOR GENE;

ANIMALS; AZOXYMETHANE; COLONIC NEOPLASMS; DIMETHYLHYDRAZINES; GENES, P53; GENES, RAS; MALE; MUTAGENS; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; RATS; RATS, INBRED F344;

ANIMALIA;

EID: 0030849321     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199707)19:2<137::AID-MC8>3.0.CO;2-C     Document Type: Article

References (41)

1. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61:759-767, 1990.
2. Stopera SA, Murphy LC, Bird RP. Evidence for a ras gene mutation in azoxymethane-mduced colonic aberrant crypts in Spra- gue-Dawley rats: Earliest recognizable precursor lesions of experimental colon cancer. Carcinogenesis 13:2081-2085, 1992.
3. Pretlow TP, Brasitus TA, Fulton NC, Cheyer C, Kaplan EL. K-ras mutations in putative preneoplastic lesions in human colon. J Natl Cancer Inst 85:2004-2007, 1993.
4. Vivona AA, Shpitz B, Medline A, et al. K-ras mutations in aberrant crypt foci, adenomas and adenocarcinomas during azoxymethane-indueed colon carcinogenesis. Carcinogenesis 14:1777-1781, 1993.
5. Bos JL, Fearon ER, Hamilton SR, et al. Prevalence of ras gene mutations in human colorectal cancers. Nature 327:293-297, 1987.
6. Yamashita N, Minamoto T, Ochiai A, Onda M, Esumi H. Frequent and characteristic K-ras activation and absence of p53 protein accumulation in aberrant crypt foci of the colon. Gastroenterology 108:434-440, 1995.
7. Baker SJ, Preisinger AC, Jessup JM, et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 50:7717-7722, 1990.
8. Ohue M, Tomita N, Monden T, et al. A frequent alteration of p53 gene in carcinoma and adenoma of colon. Cancer Res 54:4798-4804, 1994.
9. Kastrinakis WV, Ramchurren N, Rieger KM, et al. Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression. Oncogene 11:647-652, 1995.
10. Maskens AP. Histogenesis and growth pattern of 1,2-dimethylhydrazine-induced rat colon adenocarcinoma. Cancer Res 36:1585-1592, 1976.
11. Fiala ES. Investigations into the metabolism and mode of action of the colon carcinogens 1,2-dimethylhydrazine and azoxymethane. Cancer Res 40:2436-2445, 1977.
12. Ahnen DJ. Are animal models of colon cancer relevant to human disease. Dig Dis Sci 30(Suppl):103S-106S, 1985.
13. Benrezzak O, Madarnas P, Pageau R, Nigam VN. Antitumor efficacies of maltose tetrapalmitate immunotherapy alone and in combinations with radiotherapy and with cyclophosphamide chemotherapy against dimethylhydrazine induced colon and anal cancers in CD1 mice. Anticancer Res 8:499-506, 1988.
14. Nordlinger B, Panis Y, Puts JP, Herve JP, Delelo R, Ballet F. Experimental model of colon cancer: Recurrences after surgery alone or associated with intraperitoneal 5-fluorouracil chemotherapy. Dis Colon Rectum 34:658-663, 1991.
15. Boone CW, Kelloff GJ, Malone WE. Identification of candidate cancer chemopreventive agents and their evaluation in animal models and human clinical trials: A review. Cancer Res 50:2-9, 1990.
16. Greenwald P, Kelloff GJ, Boone CW, McDonald SS. Genetic and cellular changes in colorectal cancer: Proposed targets of chemopreventive agents. Cancer Epidemiol Biomarkers Prev 4:691-702, 1995.
17. Stopera SA, Bird RP. Immunohistochemical demonstration of mutant p53 tumour suppressor gene product in aberrant crypt foci. Cytobios 73:73-88, 1993.
18. Tendier Y, Reshef R, Cohen I, et al. Histochemical studies of progressive p53 mutations during colonie carcinogenesis in Sprague-Dawley rats induced by N-methyl-N-nitro-nitrosoguanidine or azoxymethane. Pathobiology 62:232-237, 1994.
19. Okamoto M, Ohtsu H, Miyaki M, Yonekawa H. No allelic loss at the p53 locus in 1,2-dimethylhydrazine-induced mouse colon tumours: PCR-SSCP analysis with sequence-tagged microsatellite site primers. Carcinogenesis 14:1483-1486, 1993.
20. Okamoto M, Ohtsu H, Kominami R, Yonekawa H. Mutational and LOH analyses of p53 alleles in colon tumors induced by 1,2-dimethylhydrazine in F1 hybrid mice. Carcinogenesis 16:2659-2666, 1995.
21. Hollstein M, Rice K, Greenblatt MS, et al. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 22:3551-3555, 1994.
22. Wright DK, Manos MM. Sample preparation from paraffin-embedded tissues. In: Innis MA, Gelfand DH, Sninsky JJ, White TH (eds), PCR Protocols: A Guide to Methods and Applications. Academic Press, New York, 1990, pp. 153-158.
23. Sambrook J, Fritsch E, Maniatis T. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989, pp. 9.14-9.19.
24. Soussi T, Caron de Fromentel C, May P. Structural aspects of the p53 protein in relation to gene evolution. Oncogene 5:945-952, 1990.
25. Toneguzzo F, Glynn S, Leyi E, Mjolsness S, Hayday A. Use of a chemical modified T7 DNA polymerase for manual and auto- mated sequencing of supercoiled DNA. BioTechniques 6:460-469, 1988.
26. Jiang W, Kahn SM, Guillan JG, Lu S-H, Weinstein JR. Rapid detection of ras oncogenes in human tumors: Application to colon, esophageal, and gastric cancer. Oncogene 4:923-928, 1989.
27. Vogelstem B. Rapid purification of DNA from agarose gels by centrifugation through a disposable plastic column. Anal Biochem 160:115-118, 1987.
28. McCabe P. Asymmetric PCR. In: Innis MA, Gelfand DH, Sninsky JJ, White TH (eds). PCR Protocols: A Guide to Methods and Applications. New York, Academic Press, 1990, pp. 76-83.
29. Neri A, Knowles DM, Greco A, McCormic F, Dalla-Favera R. Analysis of RAS oncogene mutations in human lymphoid malignancies. Proc Natl Acad Sci USA 85:9268-9272, 1988.
30. Nelson MA, Futscher BW, Loew MR, Bowden GT. Analysis of the Harvey-ras gene in cisplatin-induced mouse skin tumors by polymerase chain reaction and direct DNA sequencing. Cancer Lett 65:27-33, 1992.
31. Hulla JE, Schneider RP. Structure of the rat p53 tumor suppressor gene. Nucleic Acids Res 21:713-717, 1993.
32. Nigro JM, Baker SJ, Presinger AC, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 342:705-708, 1989.
33. Druckery H. Production of colonic carcinomas by 1,2-dial-kylhydrazines and azoxyalkanes. In: Burdette WJ (ed). Carcinoma of the Colon and Antecedent Epithelium, Charles C. Thomas, Springfield, IL, 1970, pp. 267-279.
34. Kinzler KW, Vogetstein B. Lessons from hereditary colorectal cancer. Cell 87:159-170, 1996.
35. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825, 1993.
36. Han J, Sabbatini P, Perez D, Rao L, Modha D, White E. The E1B 19K protein blocks apoptosis by interacting with and inhibiting the p53-mducible and death-promoting Bax protein. Genes Dev 10:461-477, 1996.
37. Suzui M, Yoshimi N, Ushijima T, et al. No involvement of Ki-ras or p53 gene mutations in colitis-associated rat colon tumors induced by 1-hydroxyanthraquinone and methylazoxymethanol acetate. Mol Carcinog 12:193-197, 1995.
38. Makino H, Ushijima T, Kakiuchi H, et al. Absence of p53 mutations in rat colon tumors induced by 2-amino-6-methyldipyrido[ 1,2-a:3′ ,2′ -djimidazole, 2-amino-3-methyltmidazo[4,5-f] quinoline, or 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Jpn J Cancer Res 85:510-514, 1994.
39. Ushijima T, Makino H, Okonogi H, Hosoya Y, Sugimura T, Nagao M. Mutation, loss of heterozygosity, and recombination of the p53 gene in mouse forestomach tumors induced by 2-amino-3,4-dimethylimidazo[4,5-f]quinoline. Mol Carcinog 12:23-30, 1995.
40. Shivapurkar N, Belinsky SA, Wolf DC, Teng Z, Alabaster O. Absence of p53 mutations in rat colon carcinomas induced by azoxyrnethane. Cancer Lett 96:63-70, 1995.
41. Tornaletti S, Pfeifer GP. Slow repair of pyrimidine dimers at p53 mutation hotspots in skin cancer. Science 263:1436-1438, 1994.